Semiannual index

U

R O

LO

AUTHORINDEX

~----~~VOLUMEXXXIV,JULYTODECEMBER1989

Pages 1-68 69-114 115-170 171-230

Addonizio, J. C., 205 Ahn, J. ]!t., 383 Akiyama, T., 258 Allen, J., 197 Alvarez, l., 4.(} Ashton, ]. J., 187 Asirwatham, J. E., 159 Avitable, A. M., 51 Ayala, A. G., Suppl (6), 52; 310, 339 Babaian, R. J., Suppl (6) 52; 339 Badalament, R. A., 120, 187 Baer, H. M., 33 Bagley, D. It.. 197 Bak, M., 181 Baldingcr, S., 265 Baltish, M. B., 197 Barjenbruch, O.. 193 Bavendam. T., 56 Benson, M. C., 353 Bergman, A., 200 Bergman, B., 241 Bhatia, N. N , 2qX) Bhola, A., 168 Bostwick, D. G., Suppl (6) 16 Bracken, R. B., 349 Braf, Z., 301 Brausi, M., 115 Brawer, M. K., Suppl (6) 62 Brendler, C. B., 69 Brenner, D. \~L, 93 Brooks, M. B., 225 Carroll, J. L., 1!)7 Carroll, J. T., Suppl (6) 4 Cass, A. S., 249 Castaneda-Zuniga, W., 139 Causey J. Q., 175 Cavalieri, S., 227 Chancellor, M., 18 (]hang, L. S., 18 Charnsangavej, C. J., 171 Chiao, ]. W., 205 Chinn, S., 381 Chodak, G. %(, Suppl (4) 3, 10, 84, 87 Christensen-Da). ('., Suppl (6) 4 Churchill, B. M., 62 Clayton, M., 381 Cockett, A. T. K., 376 Cohen, M., 58 Connor, J. E, 353 Costertoo, J W, 284

UROI,()CY

Issue

Court, B. H., 281 Cox, C. E., 322 Crawford, E. D., Suppl (4) 3, 22, 46 Cunningham, D. L., 109 Cunningham, J. J., 316 Daloni, P., 357 Daricello, G., Suppl (4) 27 Davis, C. J., Suppl (6) 49 Day; C., See Christensen-Day, C. Debruyne, E M. J., 123 Diokno, A. C., 18, 277 DiPhillipo, M. A., 297 Donohue, J. R, 396 Downey', J. A., 284 Drago, J. R., Suppl (6) 2; 120, 187 Dresner, M. L., 213 Droller, M. A., 10 Droz, J. R, 281 Dunphy, C. H., 339 Durante, R. T., 297 Edson, M., 100 Edwards, O. E, 265 Einhorn, L. H., 396 Ellis, D. J., 197 Ellis, G. F., 262 England, D. M., 155 Eryigit, M., 129 Esa, A., 258 Esposti, P. L., 73 Farcon, E., 383 Farha, A. J., 216 Fassuliotis, T. M., 307 Feneley, R. C. L., 246 Ferro, M. A., 134 Fischer, J., 205 Flanigan, R. C.. 164 Flax, S., 62 Fontanesi, J., 76 Fowler, J. E., Jr., 96 Freiha, E, 347 Fry; J. M., 297 Gabrilove, J. L.. 10 Gansler, T. S., 51 Garnett, J. E., Suppl (6) 66 Geller, J., Suppl (4) 57 Ghosn, M., 281 Giacco, G. G., 310 Gilbert, E. 22 Gilday; D. L., 62

DECEMBER 1989

Pages

July August September October

1-96 231-327 327-402 1-69

Gillatt, D., 134 Gluck, R., 58 Godec, C. J., 152 Goldman, S. M., 390 Goldwein, M. I., 51 Golimbu, M., 106 Golomb, J., 329 Gomella, L. G., 164 Gonzales, J., 18.39 Graulau, J. M., See Hernandez-Graulau, J. M. Green, L. K., 310 Greenfield, S. P., 131 Gregg, R. V., 349 Gregory, J. G., 344 Griffin, P. P., Suppl (4) 37 Griffin, T. W., 1 Grignon, D. J., Suppl (6) 52; 310 Grossman, H. B., 18 Guinan, P., 381 Guinee, V. E, 310 [tackler, R. H., 126 Hall, M. K., 126 Hanno, P., 51 Hardeman, S. W., 175 Hartlapp, J-H., 14 Hashmat, A. I., 39 Havey, A. D., 218 Hedlund, P. O., 73 Hejka, A. G., 155 Hellstrom, P., 46 Helpap, B., Suppl (6) 28 Hendrickson, E R., 1 Hendrikx, A. J. M., 123 Hernandez-Graulau, J. M., 139 Herr, H. W., 231 Heyman, J. H., 221 Hickey, D. E, 175 Hiller, J., 152 Hohlbrugger, G., 367 Holm, H. H., 181 Holm, S. E., 241 Horne, D. W., 43 Huben, R. P., 18 Hulbert, J. C., 139 Hunter, D., 139 lseri, C., 129 Iversen, P., 181 Jacobs, M. A., 56 Jaeger, N., 14 Janetschek, G.. 367

,' VOI,UME XXXIV, NUMBER 6

Issue Supplement (4) November December Supplement (6)

Javadpour, N., 357 Jefferson Sexual Function Center, 197 Johnson, D. E., 339 Jones, G., 100 Josifidis, H. T., 131 Juul, N., 181 Kaneko., S., 258 Kaplan, P., 10 Karamalegos, A. Z., 277 Karram, M., 200 Kastendieck, H., Suppl (6) 28 Kaye, K. W., l l l Keating, M. A., Suppl (4) 37 Kessler, D. L., 349 Khan, A. R., 1131 Khan, Z., 168 Khawand, N., 100 Kim, K. S., 362 King, G. W., 18 King, L. R., 362 Kirschenbaum, A., 10 Kiser, L. C., 102 Klutke, C. G., 329 Kohri, K., 258 Konishi, T., 385 Konnak, J., 18 Kovi, J., Suppl (6) 23 Krall, J. M., l Krauss, D. J., 216 Kreder, K. J., 213 Krieger, J. N.. 1 Kuo, J. S., 28 Kurita, T., 258 Kyllonen, A. P., 46 Lange, E H., Soppl (4) 13; 274 Laramore, G. E., 1 Laursen, F., 181 Leach, G. E., 56, 399 Lee, E, Supp] (6) 2, 4 Lee, K , 376 Leiter, E., 22 l Levine. A. C., 10 Lieber, M. M., Suppl (6) 43; 238 Lin, S. N., 28 Lipman, R, A.. 227 Liu, R. S., 28 Lorigan, J., 171 Lowe, F. C., 390 LSwhagen, T., 73 Lupera, tt., 281 Luxenberg, M.. 249

402-F

Macaluso, M., See Pavone-Macaluso, M. Malin, B. T., 159 Mangano, E A., 292 Maor, M. H., 1 Markham, C. W., Suppl (6) 57 Massey, J. A., 246 Matzkin, H., 301 Mayer, R. D., 376 McLorie, G., 62 MeNeal, J. E., Suppl (6) 9 McRoberts, J. W., 164 Melzer, R. B., 36 Mennen, J., 106 Miehaels, E. K., 96 Middleton, A. W, Jr., 36 Mielnick, A., 152 Miller, G. J., Suppl (4) 5 Miller, W T., 227 Mitchell, A. E., Suppl (6) 4 Montgomery, P., 131 Moore, L. S., 274 Morales, P., 383 Mostofi, E K., Suppl (6) 2, 23, 49 Moylan, D. E, 277 Munn, C. S., 102 Muraki, J., 205 Naftulin, B. N., 76 Nagamatsu, G. R., 205 Neff, J. C., 187 Neri, R., Suppl (4) 19 Nesbitt, J. A., 120, 187 Nickel, J. C., 284 Nielsen, L., 181 Noe, H. N., 89 Nseyo, U. O., 76 Oesterling, J. E., 390 Olsson, C. A., 353 Orihuela, E., 231 Orovan, W L., 65 Orron, D. E., 221 Ottelin, J., 46 Oyasu, R., Suppl (6) 66 Pahira, J. J., 292 Paivansalo, M., 46

402-G

Papo, J., 301 Parkinson, D. R., Suppl (4) 69 Parra, R. O., 344 Parsons, C. L., 80 Patil, U., 49, 262 Pavone, C., 8uppl (4) 27 Pavone-Macaluso, M., Suppl (4) 27 Pedersen, S. T., See Torp-Pedersen, S. T. Persky, L., 109 Peterson, N. E., 148 Petrou, S. P., 164 Pontes, J. E., 18 Pressman, M. R., 297 Prout, G. R., Suppl (4) 37 Provet, J. A., 106 Quesada, J. R., Suppl (4) 80 Raife, M. J., 43 Rakhman, J., 106 Rapoport, F., 353 Rasmussen, E, 181 Ray, V., 381 Raz, S., 329 Reha, W. C., 292 Reinberg, Y., 274 Reintjes, A. G. M., 123 Reiter, R., 383 Rife, C. C., 238 Ro, J. Y., Suppl (6) 52; 310, 339 RSnstrom, L., 73 Rosemberg, S. K., 86 Ross, G., Jr., 193 Rubenstein, M., 381 Russell, K. J., 1 Ryan, E. D., 65 Sabatini, M., 106 Saranga, R., 301 Sarosdy, M. E, 396 Sawczuk, I. S., 353 Searzella, G. I., 388 Schellhammer, P. E, 93 Schiff, S. E, Suppl (4) 37 Schlegel, E N., 69 Sehmidt, S. S., 305 Sehnall, R. I., 33

Schwartz, B. R., 349 Seidmon, E. J., 33, 162 Sen, S. E., 129 Serretta, V., Suppl (4) 27 Sesterhenn, I. A., Suppl (6) 49 Sheff, C. D. H., 213 Siami, P., 381 Siders, D. B., Suppl (6) 4 Sidhu, G., 144 Siniluoto, T., 46 Skowronski, T., 370 Smith, H., 193 Smith, J. J., 187 Smith, P. J. B., 134 Snow, B. W., 270, 360 Soloway, M. S,, 115, 175 Spiegel, R. J., Suppl (4) 75 Spudis, E. V., 370 Stanley, M. W., 73 Stauffer, C. W, 80 Steinkohl, W. B., 399 Stief, C. G., 252 Stillwell, T. J., 238 Stoller, M. L., 305 Stone, N. N., Suppl (4) 64 Stower, M. J., 246 Stratton, M. J., 50 Stubbs, A. J., 370 Sujka, S. K., 159 Surya, B., 144 Susskind, M. R., 362 Swanson, D. A., 310, 339 Symes, M. O., 134 Takeuchi, H., 385 Tarabuley, E., 102 Tenney, D. M., 339 Theodore, C., 281 Thomas, F. S., 1 Tiwary, C. M., 210 Tomaszewski, J. E., 51 Tomoyoshi, T., 385 Torp-Pedersen, S. T., Suppl (6) 4; 181 Torti, E, 347 Treiber, U., 22 Troncoso, E, Suppl (6) 52 Tully, R. J., 218 Tyagi, G., 102

UROLOGY /

DECEMBER 1989 /

Umekawa, T., 258 Vahlensieck, W., 14 van Dijk, M. A. A. M., 123 van Dommelen, C. A. M., See van Helvoort-van Dommelen, C. A. M. van Helvoort-van Dommelen, C. A. M., 123 Vaught, W W, 43 vonder Maase, H., 181 von Eschenbach, A.C., Suppl (6) 52; 339 von Hoff, D. D., 326 Waid, T. H., 164 Warner, R., 58 Washecka, R., 144 Weaver, D., 193 Weaver, D. J., 218 Wedren, H., 241 Wein, A. J., 227 Weinstein, S., 193 Weinstein, S. H., 218 Weissbaeh, L., 14 Wetterauer, U., 252 Wetzner, S. M., 102 Whitfield, J. D., 89 Whitmore, W. E, Jr., 231 Wibault, P., 281 Wientjes, M. G., 187 Wikert, G. A., 213 Wilson, T. M., 43 Wishnow, K. I., 171,339 Witherington, R., 307 Wood, T., 271 Yeh, S. H., 28 Yore, L. M., 93 York, J. P., 187 Yu, P. C., 18 Zampieri, J. B., 126 Zampieri, T. A., 126 Zappala, S. M., 50 Zeman, R. K., 292 Zimmern, E E., 50 Zuniga, W., See Castaneda-Zuniga, W

VOLUME XXXIV, NUMBER 6

SUBJECT INDEX Abnormalities/Anomalies megalourethra, scaphoid, normal corpus spongiosum, 271 multicystic kidney', infant hypertension, 362 neonatal, obstructed contralateral ureter, 36 polycystic autosomal dominant kidney disease, perinatal, 265 prostatic dysplasias, premalignant adenocareinoma, Suppl. (6), 4,9 Von-Hippel landau syndrome, two brothers, 301 Abscess, perinephritic, following ESWL, 277 renal carbuncle, pediatric, antibiotic therapy vs surgical drainage, 89 splenic, pereutaneous nephrostomy complication, 274 Adrenal androgen suppression, prostate cancer, combined therapy, dihydrotestosterone, Suppl. (4), 22, 57 Alpha interferon, and interleukins, treatment of renal and bladder carcinomas, Suppl. (4), 87 overview: efficacy/safety/toxicity in therapy of malignancies, Suppl. (4), 75 Amyloidosis, urethral, mimicking carcinoma, rare, conservative therapy, 106 Analgesia, continuous postoperative epidural infusion, urologic surgical pain, 349 Anesthesia, "'tagged" (indigo carmine) local anesthetic, transurethral surgery,, 305 Anomaly(ies), see also abnormalities/anomalies Asbestos exposure, involvement in testicular malignant mesothelioma, 11)2 Aspergillosis, prostatic, primary~ rare, 100 renal, primary, 152 Bacillus Calmette-Guerin (BCG), intravesical, metastatic bladder TCC, 381 intravesical therapy', causing squamous cell bladder cancer, 93 second primary malignancy (Letter/Reply), 113 TC( ] of bladder/prostate/urethra, 231 Benign prostatic hypertrophy (BPH), antiandrogen flutamide, multicenter randomized, double-blind study, Suppl. (4), 64 overview: dihydrotestosterone/5 alpha-reductase levels, prosrate atrophy, estrogen withdrawal, Suppl. (4), 57 Biopsy gun (Bioptyi, precise prostate biopsy; 111 Bladder ghltathione (GStt) depletion therapy, increased antitumor effect fo cytotoxic drugs, murine, 376 interst~itial cystitis, urodynamies, 41 women, 399 leiomyoma, stress urinary incontinence, 56 safety of intravesical instillation of 10% formalin, 50 TCC, metastatic, hematologic toxicity/histopathologie changes, M-VAC chemotherapy, 353, 357 urinary" retention due to BPH, leuprolide acetate vs surgery, 69 Bladder cancer, see also bladder carcinoma Bladder cancer, M-VAC chemotherapy, hematologic toxicity/histopathologic changes, 353, 357 pretreatment buthionine sulfoximine (BSO), GSH depletion, enhancement of antitumor effect of cytotoxic agents, 376 seriou,; side effects (renal failure/bladder fibrosis) after intravesical mitomyein C therapy', 216 TCC, bladder diverticula, CT evaluation, 390 intravesical BCG, prostate, urethra involvement. 231 invasion of prostate, intravesical BCG, 381 Bladder carcinoma, see also bladder cancer Bladder carcinoma, causing annular constriction/rectal obstruction, treatment options, 238 metastatic at)~pical bilateral pulmonary transitional cell lesions, 148 squamous cell, following BCG intravesical therapy; 93 superficial transitional cell carcinoma in situ (CIS), intravesical interferon, Suppl. (4), 84 transitional cell carcinoma, superficial, stages, IVP/VCUG surveillance, upper tract disease, 193

UROI,(~(,Y

i DECEMBER 1989 /

Bladder carcinoma, long-term follow-up, single vs combination chemotherapy: methotrexate/vinblastine/doxorubicin/cisplatin (M-VAC) hematologic toxicity, 353, 357 Bladder outlet obstruction in Wegener granulomatosis, 43 Bladder substitution, continent urinary diversion, review: complications/methods/patient selection, 329 Breech delivery resulting in testicular injury, 166 babies, 210 Calculus(i), Candida albieans fungi in infected bladder stone, antibiotic-induced flora changes, 385 renal cystine, combined ultrasonic-electrohydrolic lithotripsy, 213 percutaneous nephrolithotomy, 139 renal, large volume, ESWL monotherapy; efficacy/morbidity, 96 Candida albicans infection in bladder stone, long-term antibiotic therapy, 385 Carbuncles, renal, children, antibiotic therapy vs surgical drainage, 89 Catheter(s), balloon, perirenal fixation, percutaneous nephrostomy, 367 Foley catheter drainage and vesicoureteral reflux causing renal calculi, 126 long-term indwelling, causing urethral damage, 246 new antegrade ureteral stent, advantages, 162 Catheter-related UTI, glycocalyx enclosed bacteria in biofilm, SEM/TEM documented, 284 Cavernosonography diagnosis of venous leakage, erectile dysfunction, impotence, 252 Cavernous vein ligation, erectile dysfunction, (?) impotence, 116patient follow-up, 22 Cefixime vs trimethoprim-sulfamethoxazole, uncomplicated lower UTI, 100-patient study, 322 CT diagnostic accuracy in renal artery trauma, 249 Cystinuria causing renal calculi, pereutaneous vs ESWL removal, 139 Cystitis, interstitial, urodynamic evaluation, 41 women, 399 Cystolitholapaxy, Foley catheter drainage, bladder stones, 126 Cytokines: interferons/interleukins/tumor necrosis factor; origins, mechanisms, antitumor activities, Suppl. (4), 69, 75, 87 Cytology, fine-needle vs core needle biopsy, diagnostic accuracy in prostate carcinoma, 73 Diverticula, bladder, TCC invasion, preeperative CT staging, 390 congenital anterior urethral, 21-year-old male, 129 DNA ploidy analysis, prostate adenoearcinoma tumor progression rate, Suppl. (6), 43 Duet-acinar dysplasia in prostatc carcinogenesis, diagnostic criteria, histochemistry; Suppl. (6), 9 Eethyma gangrenosum, penile, heroin drug addiction, arterial sepsis, 109 Estrogen/progesterone binding activity in renal cell carcinoma, histio-biochemical techniques, 65 ESWL, induced perinephric abscess, 277 monotherapy vs combination therapy, large-volume renal stones, 96 Fluorouracil 5 % (Efudex), topical, sexually transmitted papillomavirus, 86 Flutamide, antiandrogenie effect on prostate hyperplasia, Suppl. (4), 19 effective monotherapy, untreated metastatic prostate carcinoma, long-term, Suppl. (4), 37 therapy in benign prostatic hypertrophy (BPH), double-blind study', limited side effects, no impotence, Suppl. (4), 64 Foreign bodies, urethral/bladder, endoscopic removal, Wolf nephroscope, trifurcated grasper, 3.3

VOLUME XXXIV, NUMBER 6

402-H

Germ cell testieular cancer, place of postorchiectomy surveillance, 339, 347 Germ cell tumor, retroperitoneal metastasis, polyehenmtherapy risks/benefits, 14 Hemibody irradiation (HBI), pain control, hormonal refractory metastatic prostate cancer, 76 Hemorrhagic primary transitional cell carcinoma in situ, renal pelvis, post nephrectomy cytologic diagnosis, 39 HIV (human immunodeficiency virus), antiviral activity of alpha interferon, Suppl. (4), 75 Horseshoe kidney, renal cell carcinoma, Turner syndrome, 46 Hypertension, pediatric risk in retained multicystic kidney, nephreetomy, 362 Hypospadias repair, one-stage, 100-patient review, 262 persistent ehordee, transverse corporeal plication, 360 simple effective penile dressing, 49 Impotenee, erectile dysfunction, cavernous venous ligation, 22 erectile dysfunction, penile prosthesis, new guided dilators, 225 venous leakage, eavernosonography, Doppler, 252 neurogenie vs vascular, penile dorsal nerve stimulation, cerebral-evoked response, diabetes, 370 nocturnal penile tumescence, false positive readings, 297 organic/psychogenic, Snap-Gauge band test, tumescence/rigidity, 197 vaseulogenic, diagnosis via Xenon-133 papaverine test, 28 Incontinence, urinary, in myasthenia gravis patients after TUBE 168 urinary; stress, Burch/Pereyra retropubie urethropexy; 200 urethral closure management of indwelling catheter danaage, 246 Indigo carmine:lidocaine, "tagged" local anesthetic, transurethral surgery, 305 Infertility, male, fibronectin level in ejaenlate, vasectomy patients, 80 Instruments, automatic gun (Biopty), prostate biopss, 111 new antegrade ureteral stent, uses, 162 new corpus eavernosum dilator, 225 Snap-Gauge band, impotence evaluation, 197 Wolf nephroscope, endoscopic removal of urethral/bladder foreign bodies, 33 Interferons, antitumor activity in renal cell carcinoma, Suppl. (4), 69, 80 Interleukin 2 (IL-2) and lymphokine activated killer (LAK) combined immunosuppressive therapy, renal cell carcinoma, 205 Kidne); multieystie, infant hypertension, 362 multicystic, Potter type II, neonatal, obstructed contralateral ureter, azotemia, 36 polycystic, autosomal dominant, prenatal onset, genetic counseling, 265 Leiomyoma, bladder, stress urinary incontinence, histology.; 56 Leiomyosareoma, serotal, rare, wide local excision, 144 Lithotripsy, combined eleetrohydraulie/ultrasonic, cystine renal stones, 213 Lymphadeneetom~; postsurgical lymphocele, percutaneous catheter drainage, 221 Malakoplakia, with prostatic adenoearcinoma and multiple ahscesses, immunosuppression, 159 Megalourethra, seaphoid, normal corpus spongiosuin, histologic/ embryologie implications, 271 Mesothelioma (adenomatoid), testicular malignancy, asbestos exposure, 102 Mitomycin C intravesical therapy for bladder cancer, serious side effects, 216 Myasthenia gravis, urinary incontinence after TURE 168 Nephreetoms, radical vs partial, renal cell carcinoma, diseasefree survival, angiograms, 171

402-I

Nephrolithiasis, cystine hard stones, ultrasonie-electrohydraulie lithotripsy, 213 Nephroston.}, pcrcutaneous, pcrirenal balloon catheter fixation, 367 percutaneous, splenic abscess complication, CT, 274 Nocturnal penile tumescence (NPT), impotence evaluation, false positive interpretations, 297 Nuclear grading predicting biologic potential, renal cell carcinoma Stage I, 310 Orehiectom~; Stage I germ cell testicular tumor, post-surgery surveillance with/without lyinphadenectomy/ehemotherap?; 339, 347 Penile prosthesis, erectile dysfunction, corpus eavernosum, new guided dilator, 225 inflatable, transscrotal approach, improved technique, 307, 388 implant AMS 700CX, transverse scrotal approach, 388 Penis, ecthyma gangrenosum, heroin drug addiction, 109 erectile dysfupetion, impotence, dorsal vein ligation, 22 hypospadias repair, dressing, 49 one-stage procedure, current concepts/review of 100 patients, 262 papillomavirus infection, recurrent, sexually transmitted, topical 5-FU (Efudex), 86 Snap-Gauge band test, organic vs psychogenic impotence, 197 technique to overcome persistent ehordee during hypospadias repair, 360 vasculogenic impotence, diagnosis by Xenon-133 papaverine test, 28 Polychemothcrap~; metastatic germ cell tumors, risk vs cure rate, 14 Polycystie kidney disease, autosomal dominant, perinatal, 265 Potter type II multieystie kidne:,; obstructed ureter, azotemia, 36 Prostate, aspergillosis with acute prostatic obstruction, rare, 100 atypical prostatic hyperplasia, cellular changes, clinical followup, Suppl. (6), 66 benign prostatic hypertrophy (BPH), antiandrogenic effect of flntamide, Suppl. (4), 19 luteinizing hormone-releasing hormone (LH-Rtt) agonist, 69 nonsurgical treatment with LH-RH agonist, leuprolide acetate, 69 PSA levels during leuprolide therapy,; medical castration, 10 biopsy; automatic gun (Biopty), technique, 111 dysplasia/hyperplasia, premalignant carcinoma, (?) histologic terminolog), Suppl. (6), 52 malakuplakia, with adenocarcinoma and multiple abscesses, 159 planimetric volumetry via transreetal ultrasonograph); aecura%; cadavers, 123 Proceedings of Workshop NPCP: Prostatic Intraepithelial Neoplasia: Significance and Correlation with Prostate-Specific Antigen and Transrectal Ultrasound, Suppl. (6), 1-66 signet ring cell adenucarcinoma, histochemieal/eleetron microseopic documentation, 155 Wegencr grannlomatosis, diagnostic difficulties, eytotoxic drugs, 43 Prostate aden¢~'areinoma, nuclear DNA ploidy analysis, tumor progression, prostate dysplasia, Suppl. (6), 43 PIN in 100 cystoprostatectomy specimens, re-biopsy follow-up, Suppl. (6), 52 Prostate cancer, s'ee also prostate carcinoma Prostate cancer, advanced, androgen suppression, combined ~s monotherapy; Suppl. (4), 22, 57 advanced metastatic, high-dose IV estrogen therapy, PSA levels, 134 antiandrogens, mono-, combination therapy steroidal, nonsteroidal, review, Suppl. (4), 27 carcinoma grade vs dysplasia, PIN, fine-needle biopsy (FNBx), Suppl. (6), 57 controversial treatment options: radiation vs radical prostatectomy, LttRtt vs LHRtt plus flutamide, DES risk of thrombophlebitis, Suppl. (4), 46

UROI,OGY /

DECEMBER 1989 /

VOLUME XXXIV, NUMBER 6

Prostate ( al}ccr. localize(t, ~2'h}dinc seeds, interstitial radiotherap3, selection criteria, 18l locally adwmced (Stages C, D1), fast neutron radiotherap> 1 malignant potential: tmnor volunm/histoh}gie Krade, Suppl. (4), ,5 metastatic, hormonal refract{yr,; palliative hemib{}dv irradiation (ttBI}, 76 prema'.iranant adenocarcinoma, prostatic intraepithelial neoplasia (PlNt, PSA levels, transreetal ultrasound follow-up, Sut}pl. {6), 4, 9 pr{}s/eons early detection screening: DRE/PSA/TRUS, Suppl. (4), 10 l}rostate-urethra snrxcillance after intravesical BCG therapy f(¢ bladder TCC, 231 I'SA, measuring response to IV estrogen theraps; 134 revealing persistent disease, management, Suppl. (4), 13, 46 radiation therapy, mixed beam vs conventional photon, 1 screening for early detection, ideal screening population (?). S~q)pl. (4), 4f} TCC invasion from bladder, [)ladder neck resection, intravcsical BCG, 381 transreetal ultrasound (TRUS), early' detection, 58. 120 tttmor sta~e prediction, preprostateetomy value. 175 variations in staking and grading among cancer study groups, Suppl. (4). 46 Prostate earcinnlna, S(!{'oLso prostate cancer t'rostatc carcinoma, atypical prostatic hyperplasia, PAS, transrectal ultrasound, Stlppl. (6), 66 exterI~al [)can} radiation therapy, adjuvant Estraeyt/Cytoxan, F,rogressinn/eom plicatinns, 115 fine-needle aspiration biopsy accnracy~ 30-patient follow-up, 7:3 localized to pelvis, external beam radiation, adjuvant ehemotherap?,, 115 localized, prnstatectomy vs radiation, Suppl. (4), 13 metastatic tmtreated, long-term fhttamide monotherap}; (?) impotence, Suppl. (4), 37 PIN, invasive carcinoma, 100 cystoprostateetom?, specimens, Sul}ph (61, 52 prcmalignant vs frank carcinoma, duet-acinar dysplasia, diagn{}stic criteria, Suppl. (6), 9 PSA/PAP levels, correlation with TRUS and Gleason scores, tuinor markers, 187 Radiation Therapy OncolokT Group (RTOG), Phase 1II study fast neutron ra{tiotherap3; 1 signe'~ ring cell adenneareinoma documented, 15,5 StaK{: AI, post TUR, transrectal ultrasound biopsy detection of residual lumnr, 344 THUS, ~:~Io{tineseed implantati{m, external irradiation, localized disease, 181 ultra,{mnd echo tmnor staging: hyper-, is.}-, aim hypneehok,, } 75 Prostate hyperplasia, atypical: aeinar/cribriform/intraepitbelial m,nplasia, premalignant aden{~carcinnma, histologic diagnosis, follo,~'-up, Suppl. (6), 2:3, 28 mali,,nant ItlNIC), pathologic differentiation, AFIP stud), 2:31 specimerls with follow-up, Suppl. (6), 49 Prostate-specific anti~{en (PSA), benign prostatic hypertrophy, {,nRl I analogue treatment, 1(} correlation with benign prostatic byperi}lasia, Suppl. (61, 62 post radical prostatectomy, Suppl. (4), 13 prostatie intraepithelial neoplasia (PIN}, 16, Sul}pl. (6), 4 PSA and PAP evaluation of prostate malign)he3; 187 Prostatic intrael}ithelial neoplasia (PIN), correlati{m with earcinolna in fine-needle biops}; Suppl. (6), 57 (h,finiti~e tcrnfinolo~y re lesion size/PSA level/histocyt{}lolzy,' ~radinf{, ultras{}und follow-up, Suppl. (6), 2, 4 vs t![MC studies, histopathologic cell eham{cs in hyperplastie prostate ~zlands, AFIE Suppl. (6), 4,{} prciT}alifznant adenocareinoma, clinical e.vt{}h}
UR{}I~{}{;'t /

I}ECEMBER 1,98.{} :

t'rostatic intraet}ithelial neoplasia (PIN). transreetal ultrasound biopsy of hypoechoic lesions, follow-up, Suppl. (6), 4 Pmstatism, leuprolide, PSA levels as response predictor, 1{} transvesical vs transurethral prostateetomy, incontinenee in myasthenia gravis patients, 168 Pr{}statitis, chronic, Staphyloeoceus saprophyticus., seasonal variation, co-trimoxazole, 241 Radi{muelide renal scans compared with IVU in pediatric renal trauma diagnosis, 62 Rectal obstruction secondary to bladder cancer, fascia of Denonvillier penetration, 288 Renal artery injuries, CT diagnostic accuracy, 249 Renal aspergillosis, primar> fungal, UTI, ureteropelvie obstruction, 152 Renal calculi, caused by eystinuria, percutaneous vs ESWL removal, 139 ESWL monotherapy vs combination therapy., large volume stnnes, 96 spinal cord injur~, vesicoureteral reflux, catheter drainage, 126 Ptenal carbuncles, pediatric, antibiotic therapy, 89 Renal cell carcinoma, advanced, combination chemotherapy: dacarbazine/cyclophosphamide/cisplatin/doxorubicin/vindesine; Phase II results, 281 estrogen/progesterone binding aetivit3; nonspeeifie protein binding, 65 horseshoe kidney, Turner syndrome, radiologic imaging, 46 imnmnosuppression with combined IL-2 and LAK cell therapy, 205 metastatic, antitumor activity of interferon, alone/combination, Suppl. (4), 69, 80 radical nephrectomy vs parenclwma-conserving surgery, I l l patient review, 171 Stage I, nuclear grading prognosis/survival, 310 Renal failure, bladder fibrosis, side effect of intravesical mitomyein C therapy for bladder cancer, 216 risk in rhabdomyolysis, creatinine kinase levels, 292 Renal pelvis, transitional cell carcinoma in situ, hemorrhagic, post-nephrectomy cytologic diagnosis, 39 Renal trauma, pediatric diagnostic dilemmas, IVU vs RNRS, 62 Renal vein thrombosis vs renal mass, diagnosis, 164 Rhabdomyolysis, traumatic/nontraumatic, elevated creatinine kinasc, 292 Sarcomatoid cell renal cancer, response to combined chemotherapy; 1 case, 281 Scrotal fistula, urethro-vasal reflex, spinal cord injury, paraplegic, 383 Scrotal leinmyosareoma, rare, wide local excision, 14 cases, 144 Scrotal ultrasmmd, diagnosis of rare unusual serotal lesions, 316 Semen enzme-linked immunosorbent assay (ELISA), infertility; 80 Semen fibronectin levels, male infertility', sperm agglutination, 80 Seminoma, nonpalpable occult testieular lesion, ultrasound detection, 218 Sexually transmitted papilloinavirus treated with topical 5-FU, 88 Signet rin~ cell adenocarcinoma (SRCA), prostate, immunohistochemistry/electron microscopy documentation, 155 Spinal cord injur3; Foley catheter-induced vesieoureteral reflux, renal/bladder calculi, 126 paraplegic, serotal fistula, urethrn-vasal reflex, sphincter dyssynergia, 383 Splenic abscess, gnide-wire perforation during nephrostom3; 274 Staphylococcus saprophytieus, UTI, seasonal variation occurrence in males, antibiotics, urethral flora, 241 Symposium: Advances in the Treatment of Urolo
VOI~UME XXXIV, NUMBER 6

402-J

Testicular plasmacytoma with multiple myeloma, treatment, prognosis, 51 Testicular tumor, metastatic nonseminomatous germ cell, residual tissue clonogenic growth, 396 Stage I nonseminomatous germ cell, clinical Stage I vs pathologic Stage I, postorchiectomy surveillance, 347 embryonal carcinoma, postorchiectomy surveillance, 339, 347 Testis(es), clonogenic growth, residual tissue predictor of disease process, germ cell cancer, 396 multiple myeloma, plasmacytoma, treatment, 51 nonpalpable occult tumor (seminous), ultrasound detection, 218 teratoma as predictor of relapse irl Stage I nonseminomatous germ cell tumor, postorchiectomy follow-up, 339 tunica vaginalis malignant mesothelioma, CT/ultrasound, scrotal involvement, 102 Thrombosis, renal vein, differential diagnosis, 164 Transitional cell carcinoma, bladder, superficial vs upper tract involvement, staging, IVP/VCUG surveillance, 193 in stu, recurrence rate, intravesical interferon, Suppl. (4), 84 vesical, atypical bilateral pulmonary metastases, M-VAC chemotherapy, 148 Transrectal ultrasonography (TRUS), accurately measuring prostate volume, cadavers, 123 compared with biopsy/digital examinations, prostate cancer detection, 120 prostatic intraepithelial neoplasia, Suppl. (6), 4 prostatic tumor stage prediction, sensitivity/specificity/accuracy, 175 early differential diagnosis of Stage A prostate cancer, 58 Stage A1 prostate carcinoma, post-TUR residual tumor, 344 Transscrotal insertion of inflatable penile prosthesis, improved technique, 307 Tumor markers, correlation of PIN and PSA, prostatic cancer detection, Suppl. (6), 62 PAP/PSA levels, evaluation of stage of prostate malignancies, 187 Turner syndrome, horseshoe kidney, renal cell carcinoma, rare, 46 Ultrasound detection of nonpalpable occult testicular seminoma, 218 Ureter, antireflux endoscopic injection of patient's blood, curative mechanism, 258 Ureteropelvic obstruction, fungal UTI, renal aspergillosis, 152

402-K

Ureterostomy, bioearbon implantation, indication/results/risks, 18 Urethra, amyloidosis, primary localized, mimicking carcinoma, conservative treatment, rare, 106 scaphoid megalourethra, normal corpus spongiosum, marked dorsal chordee, 271 Urethral/bladder foreign bodies, endoscopic removal via Wolf nephroscope/trifurcated grasper, 33 Urethral cancer, prostate-urethra surveillance after BCG therapy for bladder TCC, 231 Urethral closure, suprapubic drainage, neurogenic bladder, incontinence, 246 Urethral diverticulum, congenital anterior, 21-year-old male, rare, 129 Urethral resistance, after Burch or Pereyra urethropexy, 200 Urinary diversion, biocarbon cutaneous ureterostomy, stomal prosthesis, 18 continent bladder substitution, complications, review, 329 instillation intravesical of 10% formalin, risks, 50 Urinary incontinence, after TURP in myasthenia gravis patients, 168 Urinary retention, prostatic aspergillosis, diabetic, 100 Urinary tract infection, catheter-related, bacterial growth in biofilm, antibiotic resistant, 284 cefixime vs trimethoprim-sulfamethoxazole, dosages, efficacy, 100-patient randomized study, 322 inflammatory cell infiltrates in reimplanted ureter, reflux, 131 primary renal aspergillosis, ureteropelvic obstruction, 152 Urologic malignancies, (?) role of whole-lung tomography in pulmonary metastasis screening, 227 Urologic surgery, pain control by postoperative epidural analgesia, 349 Vasovasostomy, ejaculate fibronectin levels after vasectomy, (?) fertility, 80 Vesicoureteral reflux, endoscopic injection of patient's own blood, curative mechanism, new technique, 258 inflammatory cell infiltrates (ICI), UTI, 131 Voiding difficulties with urethral resistance following Pereyra or Burch urethropexy, 200 Von-Hippel Lindau syndrome, hypernephroma, pheochromocytoma, two brothers, diagnostic significance, 301 Wegener granulomatosis, renal/prostate/bladder involvement, 43 Whole-lung tomography, role in pulmonary metastasis screening, urologic cancer, 227

UROLOGY /

DECEMBER 1989 /

VOLUME XXXIV, NUMBER 6